Return to Home Incidence > Table

Incidence Rates Table

Data Options
Comparison Options

Incidence Rate Report by State

Non-Hodgkin Lymphoma (Late Stage^), 2018-2022

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Name

State
 sort alphabetically by name descending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 12.1 (12.1, 12.2) N/A 48,573 65.7
Alabama 2 8.9 (8.5, 9.2) 49 (46, 50) 550 62.8
Alaska 2 12.4 (11.2, 13.7) 28 (3, 42) 90 67.6
Arizona 2 9.7 (9.4, 10.0) 45 (44, 48) 884 63.6
Arkansas 2 11.4 (10.9, 11.9) 38 (30, 41) 429 64.4
California 7 12.0 (11.8, 12.1) 33 (27, 35) 5,326 66.3
Colorado 2 11.1 (10.7, 11.5) 39 (35, 42) 712 68.4
Connecticut 7 13.9 (13.4, 14.4) 4 (2, 12) 648 66.3
Delaware 2 12.0 (11.2, 12.9) 32 (9, 40) 160 68.8
District of Columbia 2 9.5 (8.5, 10.6) 47 (38, 51) 64 61.1
Florida 2 12.6 (12.4, 12.8) 22 (15, 30) 3,820 57.9
Georgia 7 11.8 (11.5, 12.1) 34 (28, 38) 1,376 68.1
Hawaii 7 9.6 (9.0, 10.3) 46 (41, 49) 188 65.2
Idaho 7 13.0 (12.3, 13.7) 14 (4, 33) 285 70.1
Illinois 7 12.7 (12.5, 13.0) 19 (12, 30) 1,943 67.8
Indiana 2 12.8 (12.5, 13.2) 17 (8, 29) 1,035 70.5
Iowa 7 15.3 (14.8, 15.9) 1 (1, 2) 613 71.0
Kansas 2 12.5 (12.0, 13.1) 25 (8, 35) 436 66.9
Kentucky 7 13.6 (13.1, 14.0) 6 (3, 16) 750 69.6
Louisiana 7 12.6 (12.2, 13.0) 23 (10, 33) 683 67.4
Maine 2 13.7 (12.9, 14.4) 5 (2, 24) 276 70.8
Maryland 2 11.6 (11.3, 12.0) 37 (29, 39) 855 67.4
Massachusetts 2 12.3 (12.0, 12.6) 30 (17, 35) 1,081 66.5
Michigan 2 12.6 (12.3, 12.9) 21 (13, 31) 1,611 67.9
Minnesota 2 14.3 (13.9, 14.7) 2 (1, 6) 996 64.0
Mississippi 2 10.2 (9.7, 10.7) 44 (40, 48) 360 63.5
Missouri 2 13.4 (13.1, 13.8) 7 (4, 18) 1,038 71.3
Montana 2 12.5 (11.7, 13.4) 26 (5, 38) 183 72.3
Nebraska 2 12.2 (11.5, 12.9) 31 (10, 38) 279 65.4
Nevada 2 8.0 (7.6, 8.5) 51 (49, 51) 296 56.9
New Hampshire 2 12.7 (12.0, 13.5) 18 (4, 36) 241 63.6
New Jersey 7 13.0 (12.7, 13.3) 13 (7, 24) 1,488 62.7
New Mexico 7 8.2 (7.7, 8.7) 50 (48, 51) 223 58.3
New York 7 13.0 (12.7, 13.2) 15 (9, 23) 3,214 64.0
North Carolina 2 12.6 (12.3, 12.8) 24 (13, 31) 1,583 69.9
North Dakota 2 12.7 (11.6, 13.8) 20 (2, 39) 114 68.2
Ohio 2 13.4 (13.1, 13.6) 8 (4, 16) 1,992 71.0
Oklahoma 2 11.7 (11.2, 12.1) 35 (27, 40) 543 67.3
Oregon 2 11.6 (11.2, 12.1) 36 (28, 40) 628 65.6
Pennsylvania 2 13.1 (12.8, 13.3) 12 (7, 21) 2,267 69.7
Puerto Rico 2 5.3 (5.0, 5.7) N/A 244 39.5
Rhode Island 2 12.9 (12.0, 13.8) 16 (3, 36) 182 69.1
South Carolina 2 10.4 (10.0, 10.8) 43 (40, 46) 674 66.3
South Dakota 2 13.3 (12.3, 14.4) 9 (2, 34) 145 69.9
Tennessee 2 10.5 (10.2, 10.8) 41 (39, 45) 878 61.5
Texas 7 11.0 (10.9, 11.2) 40 (37, 41) 3,277 62.7
Utah 7 12.4 (11.8, 13.0) 29 (9, 37) 364 67.2
Vermont 2 13.1 (12.1, 14.3) 11 (2, 37) 122 69.7
Virginia 2 10.5 (10.2, 10.7) 42 (40, 45) 1,071 64.8
Washington 1 12.5 (12.1, 12.8) 27 (14, 33) 1,124 66.2
West Virginia 2 13.3 (12.6, 14.0) 10 (3, 29) 336 69.3
Wisconsin 2 14.3 (13.9, 14.7) 3 (1, 6) 1,074 69.5
Wyoming 2 9.4 (8.3, 10.5) 48 (40, 51) 66 59.1

Notes:
Created by statecancerprofiles.cancer.gov on 03/23/2026 7:32 am.

State Cancer Registries may provide more current or more local data.

Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.


† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2024 submission.

2 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2024 submission).

7 Source: SEER November 2024 submission.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.

Return to Top